US2012328699A1PendingUtilityA1

Method and composition for treatment of skeletal dysplasias

54
Assignee: GOLEMBO MYRIAMPriority: Mar 20, 2001Filed: Jan 13, 2011Published: Dec 27, 2012
Est. expiryMar 20, 2021(expired)· nominal 20-yr term from priority
Inventors:Myriam GolemboAvner Yayon
C07K 2319/02A61K 35/33A61P 19/00C07K 14/61A61P 19/08A61K 48/00A61K 35/12C07K 14/58A61K 2035/128A61K 38/2242
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a method for the treatment of skeletal dysplasia by administering to a patient a composition comprising a therapeutically effective amount of at least one C-type natriuretic peptide (CNP).

Claims

exact text as granted — not AI-modified
1 . A method for the treatment of skeletal dysplasia which comprises administering to a patient a composition comprising natriuretic peptide secreting cells. 
     
     
         2 . The method according to  claim 1 , wherein the natriuretic peptide secreting cells are genetically engineered to express high levels of the natriuretic peptide. 
     
     
         3 . The method according to  claim 1 , wherein the natriuretic peptide is a C-type natriuretic peptide (CNP). 
     
     
         4 . The method according to  claim 1 , wherein the natriuretic peptide is a natriuretic peptide variant. 
     
     
         5 . The method according to  claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier or excipient. 
     
     
         6 . The method according to  claim 1 , wherein the natriuretic peptide secreting cells are transplanted or implanted to a lesion site. 
     
     
         7 . The method according to  claim 6 , wherein the natriuretic peptide secreting cells are transplanted or implanted to an affected limb bone. 
     
     
         8 . The method according to  claim 1 , wherein the natriuretic peptide secreting cells are encapsulated within an inert matrix. 
     
     
         9 . The method according to  claim 8 , wherein the natriuretic peptide secreting cells are encapsulated within an alginate-polylysine-alginate complex. 
     
     
         10 . The method according to  claim 1 , wherein the skeletal dysplasia to be treated is achondroplasia. 
     
     
         11 . The method according to  claim 1 , wherein the treatment includes controlling abnormal bone growth. 
     
     
         12 . The method according to  claim 11 , wherein the bone growth to be controlled comprises bone elongation.

Join the waitlist — get patent alerts

Track US2012328699A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.